Moody Lynn Lieberson & Walker LLC Has $22.52 Million Stock Position in Abbott Laboratories $ABT

Moody Lynn Lieberson & Walker LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 20.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 248,217 shares of the healthcare product maker’s stock after purchasing an additional 41,592 shares during the period. Abbott Laboratories makes up approximately 1.2% of Moody Lynn Lieberson & Walker LLC’s holdings, making the stock its 22nd biggest position. Moody Lynn Lieberson & Walker LLC’s holdings in Abbott Laboratories were worth $22,523,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ABT. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth $26,000. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABT. JPMorgan Chase & Co. increased their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target for the company. UBS Group lowered their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Finally, Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $118.67.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $110.68 on Tuesday. The stock has a market capitalization of $191.52 billion, a P/E ratio of 35.82, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The firm has a 50 day moving average of $98.08 and a 200-day moving average of $99.79.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the company earned $1.26 EPS. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.